knowing glucose trends in advance would give control over the disease
Across Brazil, millions of people living with diabetes carry not only the physical weight of a chronic illness but a quieter burden of anxiety, isolation, and sleepless nights shaped by glucose levels they cannot predict. A global survey has given voice to what many already knew: that the gap between available technology and accessible care is itself a source of suffering. Continuous glucose monitoring devices and AI-powered predictive tools exist and have proven their worth elsewhere in the world, yet in Brazil they remain largely out of reach for those who depend on the public health system. The question now before the country is whether the legislature will compel what the Ministry of Health has so far declined to offer.
- Seven in ten Brazilian diabetes patients report significant emotional distress, with anxiety about the future and feelings of isolation cutting deepest among those with type 1 diabetes.
- Unpredictable glucose swings fracture sleep for more than half of respondents and restrict daily life in ways that compound the psychological toll of the disease.
- Patients are not passive — nearly half are actively calling for continuous glucose monitoring and AI-powered predictive sensors to become standard care, citing prevention of complications as the driving reason.
- In January 2025, Brazil's Ministry of Health formally declined to incorporate CGM technology into the public system, leaving millions reliant on older, reactive tools.
- A bill approved by the Chamber of Deputies' Health Commission would mandate free CGM access through the public system, but it still faces financial and constitutional review before any full vote.
Seven out of ten Brazilians living with diabetes say the disease weighs heavily on their emotional wellbeing — a finding drawn from a September survey by the Global Wellness Institute and Roche Diagnostics, which included roughly 865 Brazilian respondents among more than 4,000 people across 22 countries. Nearly four in five reported anxiety about the future. Two in five felt isolated by their condition. More than half woke without feeling rested, their sleep broken by the unpredictable glucose swings that arrive in the night.
Brazil ranks sixth globally in diabetes cases, with 16.6 million adults diagnosed, yet only 35 percent of those surveyed felt genuinely confident managing their own condition. That gap is where technology enters the picture. Around 44 to 46 percent of respondents argued that continuous glucose monitoring sensors — devices that track glucose in real time and signal trends before dangerous shifts occur — should be standard care. Among those with type 1 diabetes, 68 percent identified the ability to forecast future glucose levels as the most valuable feature in AI-powered sensors, and 95 percent considered predictive tools for detecting dangerous episodes essential.
André Vianna of the Brazilian Diabetes Society explained the clinical logic plainly: knowing whether blood sugar will rise or fall in the next thirty minutes allows patients to act before a crisis, not after. The downstream effect is fewer hospitalizations, fewer emergency visits, and lower costs to the public health system. In countries like France and the United Kingdom, these devices are provided free through national health systems. In Brazil, they remain concentrated among those who can afford them privately.
In January 2025, Brazil's Ministry of Health issued a decree declining to incorporate CGM technology into the public system for either type 1 or type 2 patients. The Ministry declined to comment when asked about the decision. Yet in December, the Chamber of Deputies' Health Commission approved a bill that would require the public system to provide these devices at no cost. The proposal still faces review by financial and constitutional committees before reaching a full vote in both chambers. For now, millions of Brazilians continue managing their condition with older tools, waiting to see whether the legislature will move faster than the ministry.
Seven out of every ten Brazilians living with diabetes say the disease weighs heavily on their emotional wellbeing. That finding comes from a survey conducted last September by the Global Wellness Institute in partnership with Roche Diagnostics, which polled 4,326 people across 22 countries—roughly 865 of them Brazilian—about how they experience the disease and what tools might help them manage it better.
The emotional toll runs deep. Nearly four in five Brazilian respondents reported anxiety or worry about what comes next. Two in five felt alone because of their condition. Among those with type 1 diabetes, the figure climbed to 77 percent saying their emotional wellbeing had taken a significant hit. The practical constraints compound the psychological strain: more than half said the disease limits their ability to spend a full day away from home. Nearly half struggled with ordinary situations—sitting in traffic, enduring long meetings—where managing blood sugar becomes complicated. And 55 percent woke without feeling truly rested, their sleep fractured by the unpredictable swings in glucose that happen through the night.
Brazil ranks sixth globally in diabetes cases, with 16.6 million adults diagnosed, according to the International Diabetes Federation's 2025 atlas. Yet most patients surveyed felt the current system of care left them short. Only 35 percent said they felt truly confident managing their own condition. That gap between disease and control is where technology enters the conversation. Around 44 percent of those surveyed argued that smarter devices—ones capable of predicting glucose shifts before they happen—should be prioritized to prevent complications. Among patients currently using traditional finger-stick tests or basic glucose meters, 46 percent said continuous glucose monitoring sensors, or CGM devices, should become standard because they function as predictive alerts.
The appeal of prediction is striking. Fifty-three percent of all respondents identified the ability to forecast future glucose levels as the most valuable feature in AI-powered sensors. Among type 1 patients, that number jumped to 68 percent. The reason is straightforward: knowing glucose trends in advance would give 56 percent of Brazilian respondents a sense of control over their disease. Another 48 percent said reducing the shock of unexpected spikes and crashes would meaningfully improve their quality of life. For type 1 patients specifically, 95 percent considered predictive tools for detecting dangerous low and high blood sugar episodes to be essential.
André Vianna, vice president of the Brazilian Diabetes Society, explained why this matters clinically. Early diagnosis and continuous medical oversight are crucial to preventing complications, he said, but technology can be the difference-maker, especially for type 1 patients whose glucose levels swing wildly. Continuous glucose sensors already exist and are widely available globally. They allow patients to understand what will happen in the coming hours before it occurs—whether their blood sugar will rise or fall in thirty minutes—so they can act preventively. The payoff extends beyond individual wellbeing: patients using these sensors end up in hospitals less often, visit emergency rooms less frequently, and cost the public health system less money overall.
Yet in Brazil, these devices remain concentrated among the wealthy. Four companies sell them domestically, but the public health system has not rolled them out at scale. In wealthy nations, the picture differs sharply. The United States makes them available through private insurers; France and the United Kingdom provide them free through their national health systems. Vianna argued that sensors and AI technologies could lighten the daily burden of diabetes—the constant stress and uncertainty about what glucose will do next, the way that unpredictability disrupts sleep, work, and moments of rest. Benefits appear quickly in type 1 cases, sometimes within hours or days. In type 2 diabetes, the gains emerge over time through fewer hospitalizations and fewer complications.
In January 2025, Brazil's Ministry of Health announced it would not incorporate continuous glucose monitoring into the public health system for either type 1 or type 2 diabetes patients. The decision came via official decree. Yet in December, the Chamber of Deputies' Health Commission approved a bill that would require the public system to provide these devices free of charge. The proposal still faces review by committees on finances and constitutional matters before it can move to a full vote in both chambers. The Ministry of Health declined to comment when asked about the issue. For now, millions of Brazilians with diabetes continue managing their condition with older tools, waiting to see whether the legislature will force the government's hand.
Notable Quotes
The ideal for these patients is continuous glucose monitoring through sensors already widely available globally. The person will know if their glucose will be high or low in half an hour and can take preventive action.— André Vianna, vice president of the Brazilian Diabetes Society
These technologies can reduce the daily stress and constant uncertainty of living with diabetes, improving sleep, work, and moments of rest.— André Vianna, Brazilian Diabetes Society
The Hearth Conversation Another angle on the story
Why does the emotional piece matter so much here? It's a disease—people manage diseases all the time.
Because diabetes isn't just a metabolic problem you solve once and move on. It's a constant negotiation with your own body. You wake up not knowing if your glucose will spike or crash. You can't plan a full day away from home without anxiety. That uncertainty erodes you.
And the technology fixes that?
Not fixes, but changes the equation. If you know your glucose is trending high in thirty minutes, you can take action now instead of suffering the consequence later. It's the difference between reacting and preventing.
So why hasn't Brazil's public system adopted these sensors?
Cost, partly. But also inertia. The devices work. They're proven. They're available in France and the UK for free. Yet Brazil's Ministry of Health said no in January. Meanwhile, a bill in Congress is trying to force their hand.
What happens if the bill passes?
Suddenly millions of people who can't afford these devices get access. The emotional weight lifts a little. Sleep improves. People can plan their days. The system spends less on emergency care.
And if it doesn't?
The wealthy keep using them. Everyone else keeps waking up exhausted, keeps feeling isolated, keeps managing with tools from decades ago.